Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
Open Access
- 30 March 2023
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 112 (8) , 1056-1066
Abstract
Background: Oxidative stress may be a key pathophysiological mediator in the development and progression of heart failure (HF). The role of serum-free thiol concentrations, as a marker of systemic oxidative stress, in HF remains largely unknown. Objective: The purpose of this study was to investigate associations between serum-free thiol concentrations and disease severity and clinical outcome in patients with new-onset or worsening HF. Methods: Serum-free thiol concentrations were determined by colorimetric detection in 3802 patients from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF). Associations between free thiol concentrations and clinical characteristics and outcomes, including all-cause mortality, cardiovascular mortality, and a composite of HF hospitalization and all-cause mortality during a 2-years follow-up, were reported. Results: Lower serum-free thiol concentrations were associated with more advanced HF, as indicated by worse NYHA class, higher plasma NT-proBNP (P < 0.001 for both) and with higher rates of all-cause mortality (hazard ratio (HR) per standard deviation (SD) decrease in free thiols: 1.253, 95% confidence interval (CI): 1.171–1.341, P < 0.001), cardiovascular mortality (HR per SD: 1.182, 95% CI: 1.086–1.288, P < 0.001), and the composite outcome (HR per SD: 1.058, 95% CI: 1.001–1.118, P = 0.046). Conclusions: In patients with new-onset or worsening HF, a lower serum-free thiol concentration, indicative of higher oxidative stress, is associated with increased HF severity and poorer prognosis. Our results do not prove causality, but our findings may be used as rationale for future (mechanistic) studies on serum-free thiol modulation in heart failure. Graphical Associations of serum-free thiol concentrations with heart failure severity and outcomesKeywords
Funding Information
- European Commission (FP7-242209-BIOSTAT-CHF, EudraCT 2010–020808–29)
This publication has 44 references indexed in Scilit:
- Impact of N-acetylcysteine on Endothelial Function, B-type Natriuretic Peptide and Renal Function in Patients with the Cardiorenal Syndrome: A Pilot Cross Over Randomised Controlled TrialHeart, Lung and Circulation, 2013
- Is oxidative stress a therapeutic target in cardiovascular disease?European Heart Journal, 2010
- Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart ratsJournal of Molecular and Cellular Cardiology, 2007
- N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiencyCurrent Opinion in Pharmacology, 2007
- NADPH Oxidase Inhibitors: New Antihypertensive Agents?Journal of Cardiovascular Pharmacology, 2007
- Role of Oxidative Stress in Cardiac Hypertrophy and RemodelingHypertension, 2007
- N -Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-α Level and Hinders the Progression of Cardiac Injury in Hypertensive RatsCirculation, 2004
- Reduced Level of Serum Thiols in Patients with a Diagnosis of Active DiseaseJournal of Anti-Aging Medicine, 2003
- Heightened free radical activity in blacks with chronic pancreatitis at Johannesburg, South AfricaClinica Chimica Acta, 1994
- Potentiation of isosorbide dinitrate effects with N-acetylcysteine in patients with chronic heart failure.Circulation, 1994